InTOR - Repository of the Institute “Torlak”
Institute of Virology, Vaccines and Sera “Torlak”
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   InTOR
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   InTOR
  • Torlak
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial

No Thumbnail
Authors
Michalickova, Danica
Minić, Rajna
Dikić, Nenad
Anđelković, Marija
Kostić-Vučićević, Marija
Stojmenović, Tamara
Nikolić, Ivan
Đorđević, Brižita
Article (Published version)
Metadata
Show full item record
Abstract
A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severit...y and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.

Keywords:
Lactobacillus / upper respiratory tract illness (URTI) / CD4+/CD8+ratio / POMS
Source:
Applied Physiology Nutrition and Metabolism, 2016, 41, 7, 782-789
Publisher:
  • Canadian Science Publishing, Ottawa
Funding / projects:
  • Lallemand Health Solutions, Montreal, Canada
  • Improvement and development of hygienic and technological procedures in production of animal originating foodstuffs with the aim of producing high-quality and safe products competetive on the global market (RS-46009)
  • Allergens, antibodies, enzymes and small physiologically important molecules: design, structure, function and relevance (RS-172049)
Note:
  • Peer-reviewed manuscript: http://intor.torlakinstitut.com/handle/123456789/607
Related info:
  • Version of
    http://intor.torlakinstitut.com/handle/123456789/607

DOI: 10.1139/apnm-2015-0541

ISSN: 1715-5312

PubMed: 27363733

WoS: 000379430100013

Scopus: 2-s2.0-84977579626
[ Google Scholar ]
52
36
URI
http://intor.torlakinstitut.com/handle/123456789/476
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Torlak
TY  - JOUR
AU  - Michalickova, Danica
AU  - Minić, Rajna
AU  - Dikić, Nenad
AU  - Anđelković, Marija
AU  - Kostić-Vučićević, Marija
AU  - Stojmenović, Tamara
AU  - Nikolić, Ivan
AU  - Đorđević, Brižita
PY  - 2016
UR  - http://intor.torlakinstitut.com/handle/123456789/476
AB  - A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.
PB  - Canadian Science Publishing, Ottawa
T2  - Applied Physiology Nutrition and Metabolism
T1  - Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial
EP  - 789
IS  - 7
SP  - 782
VL  - 41
DO  - 10.1139/apnm-2015-0541
ER  - 
@article{
author = "Michalickova, Danica and Minić, Rajna and Dikić, Nenad and Anđelković, Marija and Kostić-Vučićević, Marija and Stojmenović, Tamara and Nikolić, Ivan and Đorđević, Brižita",
year = "2016",
abstract = "A randomized, double-blind, placebo-controlled study was conducted to evaluate if Lactobacillus helveticus Lafti L10 (Lallemand Health Solutions, Montreal, Que., Canada) supplementation during 14 weeks in winter can influence the duration, severity, and incidence of upper respiratory tract illness (URTI), as well as to monitor different immune parameters in the population of elite athletes. Before and after the treatment, cardiopulmonary testing and self-rated state of moods evaluation (by Profile of Mood States questionnaire) were performed and blood samples were collected. Thirty-nine elite athletes were randomized either to the placebo (n = 19) or the probiotic (n = 20) group. The probiotic group received L. helveticus Lafti L10, 2 x 10(10) Colony Forming Units. Lafti L10 significantly shortened the URTI episode duration (7.25 +/- 2.90 vs. 10.64 +/- 4.67 days, p = 0.047) and decreased the number of symptoms in the probiotic group (4.92 +/- 1.96 vs. 6.91 +/- 1.22, p = 0.035). Severity and incidence of URTI did not differ between the treatments. There were no significant changes in leukocyte subpopulation abundance, transforming growth factor-beta serum levels, level of interleukin-10 secreted from peptidoglican stimulated peripheral blood mononuclear cells (PBMCs), interferon-gamma level secreted from concanavalin A-stimulated PBMCs or viability/proliferation of PBMCs upon antigen stimulation. Group effect for CD4+/CD8+ ratio was significant (F-[1,F-37] = 6.99, p = 0.020, eta(2) = 0.350); this difference was not significant at baseline, but was evident after 14 weeks (p = 0.02). A significant interaction effect was noted for self-rated sense of vigor (F-[1,F-37] = 11.76, p = 0.009, eta(2) = 0.595). Self-rated sense of vigor increased in the probiotic group (18.5 +/- 4.1 vs. 21.0 +/- 2.6, p = 0.012). Probiotic strain Lafti L10 can be a beneficial nutritional supplement for the reduction of URTI length in elite athletes.",
publisher = "Canadian Science Publishing, Ottawa",
journal = "Applied Physiology Nutrition and Metabolism",
title = "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial",
pages = "789-782",
number = "7",
volume = "41",
doi = "10.1139/apnm-2015-0541"
}
Michalickova, D., Minić, R., Dikić, N., Anđelković, M., Kostić-Vučićević, M., Stojmenović, T., Nikolić, I.,& Đorđević, B.. (2016). Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism
Canadian Science Publishing, Ottawa., 41(7), 782-789.
https://doi.org/10.1139/apnm-2015-0541
Michalickova D, Minić R, Dikić N, Anđelković M, Kostić-Vučićević M, Stojmenović T, Nikolić I, Đorđević B. Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial. in Applied Physiology Nutrition and Metabolism. 2016;41(7):782-789.
doi:10.1139/apnm-2015-0541 .
Michalickova, Danica, Minić, Rajna, Dikić, Nenad, Anđelković, Marija, Kostić-Vučićević, Marija, Stojmenović, Tamara, Nikolić, Ivan, Đorđević, Brižita, "Lactobacillus helveticus Lafti L10 supplementation reduces respiratory infection duration in a cohort of elite athletes: a randomized, double-blind, placebo-controlled trial" in Applied Physiology Nutrition and Metabolism, 41, no. 7 (2016):782-789,
https://doi.org/10.1139/apnm-2015-0541 . .

DSpace software copyright © 2002-2015  DuraSpace
About InTOR | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About InTOR | Send Feedback

OpenAIRERCUB